BACKGROUND: CD4(+) T cells are responsible for the progressive lung damage seen in patients with chronic beryllium disease (CBD), a granulomatous lung disorder in which antigen-specific, T(H)1-type, cytokine-secreting T cells have been characterized. Compared with those seen in beryllium (Be)-sensitized subjects, increased numbers of Be-responsive T cells are present in the blood of patients with CBD. OBJECTIVE: The aim of this study was to determine whether the number of Be-specific T cells in blood predicted the development of CBD in a cohort of Be-exposed subjects. METHODS: Using IFN-γ ELISpot and proliferation-based assays, we determined the frequency and proliferative capacity of Be-responsive T cells in blood. RESULTS: Compared with the Be lymphocyte proliferation test, which detected an abnormal Be-induced proliferative response in 11 (4.2%) of 260 workers from a Be-machining facility, the IFN-γ ELISpot detected a sensitization rate of 10% (χ(2) = 55.7, P < .0001). A significant positive correlation was also noted between the number of Be-responsive CD4(+) T cells in the blood and lung tissue of patients with CBD. Importantly, the transition from Be sensitization to CBD was associated with an increased number of antigen-specific T cells in blood. CONCLUSION: These findings have important implications for Be-induced disease and potentially other immune-mediated disorders, suggesting that the frequency of antigen-specific T cells in blood can serve as a noninvasive biomarker to predict disease development and severity of the Be-specific CD4(+) T-cell alveolitis. Copyright Â
BACKGROUND:CD4(+) T cells are responsible for the progressive lung damage seen in patients with chronic beryllium disease (CBD), a granulomatous lung disorder in which antigen-specific, T(H)1-type, cytokine-secreting T cells have been characterized. Compared with those seen in beryllium (Be)-sensitized subjects, increased numbers of Be-responsive T cells are present in the blood of patients with CBD. OBJECTIVE: The aim of this study was to determine whether the number of Be-specific T cells in blood predicted the development of CBD in a cohort of Be-exposed subjects. METHODS: Using IFN-γ ELISpot and proliferation-based assays, we determined the frequency and proliferative capacity of Be-responsive T cells in blood. RESULTS: Compared with the Be lymphocyte proliferation test, which detected an abnormal Be-induced proliferative response in 11 (4.2%) of 260 workers from a Be-machining facility, the IFN-γ ELISpot detected a sensitization rate of 10% (χ(2) = 55.7, P < .0001). A significant positive correlation was also noted between the number of Be-responsive CD4(+) T cells in the blood and lung tissue of patients with CBD. Importantly, the transition from Be sensitization to CBD was associated with an increased number of antigen-specific T cells in blood. CONCLUSION: These findings have important implications for Be-induced disease and potentially other immune-mediated disorders, suggesting that the frequency of antigen-specific T cells in blood can serve as a noninvasive biomarker to predict disease development and severity of the Be-specific CD4(+) T-cell alveolitis. Copyright Â
Authors: P K Henneberger; D Cumro; D D Deubner; M S Kent; M McCawley; K Kreiss Journal: Int Arch Occup Environ Health Date: 2001-04 Impact factor: 3.015
Authors: Andrew P Fontenot; Laia Gharavi; Sean R Bennett; Scott J Canavera; Lee S Newman; Brian L Kotzin Journal: J Clin Invest Date: 2003-09 Impact factor: 14.808
Authors: Douglas G Mack; Allison M Lanham; Michael T Falta; Brent E Palmer; Lisa A Maier; Andrew P Fontenot Journal: Am J Respir Crit Care Med Date: 2010-03-18 Impact factor: 21.405
Authors: Milton D Rossman; Jose Stubbs; Chung Wha Lee; Elias Argyris; Eleni Magira; Dimitri Monos Journal: Am J Respir Crit Care Med Date: 2002-03-15 Impact factor: 21.405
Authors: Lisa A Maier; Dierdre S McGrath; Hiroe Sato; Penny Lympany; Ken Welsh; Roland Du Bois; Lori Silveira; Andrew P Fontenot; Richard T Sawyer; Eric Wilcox; Lee S Newman Journal: J Immunol Date: 2003-12-15 Impact factor: 5.422
Authors: M D Rossman; J A Kern; J A Elias; M R Cullen; P E Epstein; O P Preuss; T N Markham; R P Daniele Journal: Ann Intern Med Date: 1988-05 Impact factor: 25.391
Authors: Elizabeth Fireman; Yehuda Lerman; Moshe Stark; Asher Pardo; Yehuda Schwarz; Michael V Van Dyke; Jill Elliot; Briana Barkes; Lee Newman; Lisa Maier Journal: J Occup Environ Hyg Date: 2014 Impact factor: 2.155
Authors: Li Li; Lori J Silveira; Nabeel Hamzeh; May Gillespie; Peggy M Mroz; Annyce S Mayer; Tasha E Fingerlin; Lisa A Maier Journal: Eur Respir J Date: 2016-04-21 Impact factor: 16.671
Authors: Kerry M Hena; Jennifer Yip; Nadia Jaber; David Goldfarb; Kelly Fullam; Krystal Cleven; William Moir; Rachel Zeig-Owens; Mayris P Webber; Daniel M Spevack; Marc A Judson; Lisa Maier; Andrew Krumerman; Anthony Aizer; Simon D Spivack; Jessica Berman; Thomas K Aldrich; David J Prezant Journal: Chest Date: 2017-10-21 Impact factor: 9.410
Authors: Shaikh M Atif; Douglas G Mack; Amy S McKee; Javier Rangel-Moreno; Allison K Martin; Andrew Getahun; Lisa A Maier; John C Cambier; Rubin Tuder; Andrew P Fontenot Journal: JCI Insight Date: 2019-05-16
Authors: Douglas G Mack; Michael T Falta; Amy S McKee; Allison K Martin; Philip L Simonian; Frances Crawford; Terry Gordon; Robert R Mercer; Mark D Hoover; Philippa Marrack; John W Kappler; Rubin M Tuder; Andrew P Fontenot Journal: Proc Natl Acad Sci U S A Date: 2014-05-27 Impact factor: 11.205